Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 114

Similar articles for PubMed (Select 22977237)

1.

Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva.

Chaikuad A, Alfano I, Kerr G, Sanvitale CE, Boergermann JH, Triffitt JT, von Delft F, Knapp S, Knaus P, Bullock AN.

J Biol Chem. 2012 Oct 26;287(44):36990-8. doi: 10.1074/jbc.M112.365932. Epub 2012 Sep 12.

2.

ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation.

van Dinther M, Visser N, de Gorter DJ, Doorn J, Goumans MJ, de Boer J, ten Dijke P.

J Bone Miner Res. 2010 Jun;25(6):1208-15. doi: 10.1359/jbmr.091110.

PMID:
19929436
3.

A novel mutation of ALK2, L196P, found in the most benign case of fibrodysplasia ossificans progressiva activates BMP-specific intracellular signaling equivalent to a typical mutation, R206H.

Ohte S, Shin M, Sasanuma H, Yoneyama K, Akita M, Ikebuchi K, Jimi E, Maruki Y, Matsuoka M, Namba A, Tomoda H, Okazaki Y, Ohtake A, Oda H, Owan I, Yoda T, Furuya H, Kamizono J, Kitoh H, Nakashima Y, Susami T, Haga N, Komori T, Katagiri T.

Biochem Biophys Res Commun. 2011 Apr 1;407(1):213-8. doi: 10.1016/j.bbrc.2011.03.001. Epub 2011 Mar 4.

PMID:
21377447
4.

Molecular consequences of the ACVR1(R206H) mutation of fibrodysplasia ossificans progressiva.

Song GA, Kim HJ, Woo KM, Baek JH, Kim GS, Choi JY, Ryoo HM.

J Biol Chem. 2010 Jul 16;285(29):22542-53. doi: 10.1074/jbc.M109.094557. Epub 2010 May 12.

5.

A unique mutation of ALK2, G356D, found in a patient with fibrodysplasia ossificans progressiva is a moderately activated BMP type I receptor.

Fukuda T, Kanomata K, Nojima J, Kokabu S, Akita M, Ikebuchi K, Jimi E, Komori T, Maruki Y, Matsuoka M, Miyazono K, Nakayama K, Nanba A, Tomoda H, Okazaki Y, Ohtake A, Oda H, Owan I, Yoda T, Haga N, Furuya H, Katagiri T.

Biochem Biophys Res Commun. 2008 Dec 19;377(3):905-9. doi: 10.1016/j.bbrc.2008.10.093. Epub 2008 Oct 24.

PMID:
18952055
6.

Constitutively activated ALK2 and increased SMAD1/5 cooperatively induce bone morphogenetic protein signaling in fibrodysplasia ossificans progressiva.

Fukuda T, Kohda M, Kanomata K, Nojima J, Nakamura A, Kamizono J, Noguchi Y, Iwakiri K, Kondo T, Kurose J, Endo K, Awakura T, Fukushi J, Nakashima Y, Chiyonobu T, Kawara A, Nishida Y, Wada I, Akita M, Komori T, Nakayama K, Nanba A, Maruki Y, Yoda T, Tomoda H, Yu PB, Shore EM, Kaplan FS, Miyazono K, Matsuoka M, Ikebuchi K, Ohtake A, Oda H, Jimi E, Owan I, Okazaki Y, Katagiri T.

J Biol Chem. 2009 Mar 13;284(11):7149-56. doi: 10.1074/jbc.M801681200. Epub 2008 Aug 6.

7.

In vitro analyses of the dysregulated R206H ALK2 kinase-FKBP12 interaction associated with heterotopic ossification in FOP.

Groppe JC, Wu J, Shore EM, Kaplan FS.

Cells Tissues Organs. 2011;194(2-4):291-5. doi: 10.1159/000324230. Epub 2011 Apr 28.

8.

Alk2 regulates early chondrogenic fate in fibrodysplasia ossificans progressiva heterotopic endochondral ossification.

Culbert AL, Chakkalakal SA, Theosmy EG, Brennan TA, Kaplan FS, Shore EM.

Stem Cells. 2014 May;32(5):1289-300. doi: 10.1002/stem.1633.

PMID:
24449086
9.

The fibrodysplasia ossificans progressiva R206H ACVR1 mutation activates BMP-independent chondrogenesis and zebrafish embryo ventralization.

Shen Q, Little SC, Xu M, Haupt J, Ast C, Katagiri T, Mundlos S, Seemann P, Kaplan FS, Mullins MC, Shore EM.

J Clin Invest. 2009 Nov;119(11):3462-72. doi: 10.1172/JCI37412. Epub 2009 Oct 12.

10.

Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1.

Kaplan FS, Xu M, Seemann P, Connor JM, Glaser DL, Carroll L, Delai P, Fastnacht-Urban E, Forman SJ, Gillessen-Kaesbach G, Hoover-Fong J, Köster B, Pauli RM, Reardon W, Zaidi SA, Zasloff M, Morhart R, Mundlos S, Groppe J, Shore EM.

Hum Mutat. 2009 Mar;30(3):379-90. doi: 10.1002/humu.20868.

11.

Establishment of a novel model of chondrogenesis using murine embryonic stem cells carrying fibrodysplasia ossificans progressiva-associated mutant ALK2.

Fujimoto M, Ohte S, Shin M, Yoneyama K, Osawa K, Miyamoto A, Tsukamoto S, Mizuta T, Kokabu S, Machiya A, Okuda A, Suda N, Katagiri T.

Biochem Biophys Res Commun. 2014 Dec 12;455(3-4):347-52. doi: 10.1016/j.bbrc.2014.11.012. Epub 2014 Nov 15.

PMID:
25446088
13.

Mutational analysis of the ACVR1 gene in Italian patients affected with fibrodysplasia ossificans progressiva: confirmations and advancements.

Bocciardi R, Bordo D, Di Duca M, Di Rocco M, Ravazzolo R.

Eur J Hum Genet. 2009 Mar;17(3):311-8. doi: 10.1038/ejhg.2008.178. Epub 2008 Oct 1.

14.

[Genetic basis for skeletal disease. Establishment of novel treatments for fibrodysplasia ossificans progressiva (FOP)].

Katagiri T.

Clin Calcium. 2010 Aug;20(8):1204-11. doi: CliCa100812041211. Review. Japanese.

PMID:
20675931
15.

Fibrodysplasia ossificans progressiva-related activated activin-like kinase signaling enhances osteoclast formation during heterotopic ossification in muscle tissues.

Yano M, Kawao N, Okumoto K, Tamura Y, Okada K, Kaji H.

J Biol Chem. 2014 Jun 13;289(24):16966-77. doi: 10.1074/jbc.M113.526038. Epub 2014 May 5.

PMID:
24798338
16.

Antisense-oligonucleotide mediated exon skipping in activin-receptor-like kinase 2: inhibiting the receptor that is overactive in fibrodysplasia ossificans progressiva.

Shi S, Cai J, de Gorter DJ, Sanchez-Duffhues G, Kemaladewi DU, Hoogaars WM, Aartsma-Rus A, 't Hoen PA, ten Dijke P.

PLoS One. 2013 Jul 4;8(7):e69096. doi: 10.1371/journal.pone.0069096. Print 2013.

17.

Investigations of activated ACVR1/ALK2, a bone morphogenetic protein type I receptor, that causes fibrodysplasia ossificans progressiva.

Kaplan FS, Seemann P, Haupt J, Xu M, Lounev VY, Mullins M, Shore EM.

Methods Enzymol. 2010;484:357-73. doi: 10.1016/B978-0-12-381298-8.00018-6.

PMID:
21036241
18.

A new era for fibrodysplasia ossificans progressiva: a druggable target for the second skeleton.

Kaplan FS, Glaser DL, Pignolo RJ, Shore EM.

Expert Opin Biol Ther. 2007 May;7(5):705-12. Review.

PMID:
17477807
19.

Pathogenic mutation of ALK2 inhibits induced pluripotent stem cell reprogramming and maintenance: mechanisms of reprogramming and strategy for drug identification.

Hamasaki M, Hashizume Y, Yamada Y, Katayama T, Hohjoh H, Fusaki N, Nakashima Y, Furuya H, Haga N, Takami Y, Era T.

Stem Cells. 2012 Nov;30(11):2437-49. doi: 10.1002/stem.1221.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk